Massachusetts Biotech Secures $85 Million and Completes STRIDE Trial Enrollment

CereVasc has opened a new medical device manufacturing and research facility in Massachusetts following the completion of enrollment in its STRIDE pivotal trial and the closing of an oversubscribed $85 million funding round. The expansion scales the company’s operational capacity to support the commercialization of its neurovascular technologies.

The company’s move into the Massachusetts facility coincides with the conclusion of the STRIDE trial. According to company announcements, the trial focused on the safety and efficacy of CereVasc’s specialized devices designed for treating cerebrovascular conditions.

CereVasc Funding and STRIDE Trial Milestones

The opening of the research and manufacturing site was supported by a recent capital raise. CereVasc reported that it closed an $85 million funding round, which the company described as oversubscribed. This capital provides the liquidity necessary to transition from the clinical trial phase to large-scale production.

The STRIDE pivotal trial represents the final stage of clinical testing required before seeking regulatory approval for the device’s commercial use. CereVasc confirmed that enrollment for the trial is now complete, moving the company closer to a potential market launch.

Facility Capabilities and Strategic Location

The Massachusetts site integrates both research and development (R&D) with active manufacturing. By combining these functions, CereVasc aims to shorten the feedback loop between device design and production. The facility is equipped to handle the precision engineering required for neurovascular implants and delivery systems.

The decision to establish the facility in Massachusetts places CereVasc within a concentrated hub of biotechnology and medical device expertise. This location provides access to a specialized labor pool and proximity to academic medical centers that often participate in clinical trials for stroke and vascular interventions.

Impact on Neurovascular Device Production

The transition to a dedicated manufacturing plant allows CereVasc to move beyond the small-batch production used during the STRIDE trial. The new infrastructure is designed to meet the quality control and regulatory standards necessary for FDA and international certification.

The company’s focus remains on addressing gaps in the treatment of cerebrovascular diseases. The combined effect of the $85 million investment and the new facility is intended to accelerate the timeline for delivering these devices to clinicians and patients.